Mitoxantrone Hydrochloride

Advance Directives, Liver carcinoma, Leukemia + 10 more
Treatment
17 FDA approvals
20 Active Studies for Mitoxantrone Hydrochloride

What is Mitoxantrone Hydrochloride

MitoxantroneThe Generic name of this drug
Treatment SummaryAn antineoplastic agent derived from anthracenedione, a type of chemical compound.
Novantroneis the brand name
image of different drug pills on a surface
Mitoxantrone Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Novantrone
Mitoxantrone
1987
12

Approved as Treatment by the FDA

Mitoxantrone, otherwise known as Novantrone, is approved by the FDA for 17 uses which include Progressive Relapsing Multiple Sclerosis and Relapsed Lymphomas .
Progressive Relapsing Multiple Sclerosis
Helps manage Progressive Relapsing Multiple Sclerosis
Relapsed Lymphomas
Relapsed Leukemia
Secondary Progressive Multiple Sclerosis (SPMS)
Helps manage Secondary Progressive Multiple Sclerosis (SPMS)
Acute Myeloid Leukemia (AML)
Used to treat Acute Myeloid Leukemia (AML) in combination with null
Leukemia
Relapsing Remitting Multiple Sclerosis (RRMS)
Helps manage Relapsing Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Helps manage Secondary Progressive Multiple Sclerosis (SPMS)
relapsed Hepatocellular carcinoma
Metastatic Breast Cancer
Liver carcinoma
Metastatic Breast Cancer
Advance Directives
Multiple Sclerosis
Helps manage Progressive Relapsing Multiple Sclerosis
Lymphoma
Acute Myeloid Leukemia
Used to treat Acute Myeloid Leukemia (AML) in combination with null
Relapsing Remitting Multiple Sclerosis
Helps manage Relapsing Remitting Multiple Sclerosis (RRMS)

Effectiveness

How Mitoxantrone Hydrochloride Affects PatientsIn laboratory tests, mitoxantrone has been found to stop the growth of B cells, T cells, and macrophages and reduce the activity of certain proteins involved in immunity. It also reduces the amount of interferon gamma, TNFa, and IL-2 that are released from these cells.
How Mitoxantrone Hydrochloride works in the bodyMitoxantrone works by binding to DNA and interfering with the repair process. It binds to DNA, preventing the enzyme responsible for fixing DNA from doing its job. This stops the cell from being able to fix itself, leading to cell death. It affects both growing and inactive cells, so it is not specific to any particular stage of the cell cycle.

When to interrupt dosage

The amount of Mitoxantrone Hydrochloride is contingent upon the diagnosed state, including Metastatic Breast Cancer, Acute Promyelocytic Leukemia and Advance Directives. The dosage fluctuates as per the route of administration (e.g. Liquid or Injection, solution, concentrate) specified in the table hereunder.
Condition
Dosage
Administration
Multiple Sclerosis
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Advance Directives
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Lymphoma
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Hodgkin's Lymphoma
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Relapsing Remitting Multiple Sclerosis
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Liver carcinoma
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Leukemia
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Non-Hodgkin's Lymphoma
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Acute Myeloid Leukemia
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Metastatic Breast Cancer
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Acute Lymphoblastic Leukemia
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Multiple Sclerosis
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Acute Promyelocytic Leukemia
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution - Intravenous, Injection, solution, Solution - Intravenous, Solution, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Warnings

There are 20 known major drug interactions with Mitoxantrone Hydrochloride.
Common Mitoxantrone Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Acteoside.
Mitoxantrone Hydrochloride Toxicity & Overdose RiskAn overdose on this drug can cause a severe decrease in white blood cells, which can lead to an increased risk of infection.
image of a doctor in a lab doing drug, clinical research

Mitoxantrone Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Mitoxantrone Hydrochloride?

Presently, 785 active studies are being conducted to examine the efficacy of Mitoxantrone Hydrochloride in treating Hodgkin's Lymphoma, Metastatic Breast Cancer and Relapsed Lymphomas.
Condition
Clinical Trials
Trial Phases
Lymphoma
1 Actively Recruiting
Phase 2
Acute Myeloid Leukemia
267 Actively Recruiting
Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1
Multiple Sclerosis
21 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable
Liver carcinoma
0 Actively Recruiting
Relapsing Remitting Multiple Sclerosis
14 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 4, Early Phase 1
Leukemia
1 Actively Recruiting
Phase 1, Phase 2
Acute Promyelocytic Leukemia
0 Actively Recruiting
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Advance Directives
0 Actively Recruiting
Multiple Sclerosis
0 Actively Recruiting
Non-Hodgkin's Lymphoma
115 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4
Acute Lymphoblastic Leukemia
120 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Hodgkin's Lymphoma
63 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1

Mitoxantrone Hydrochloride Reviews: What are patients saying about Mitoxantrone Hydrochloride?

5Patient Review
6/20/2009
Mitoxantrone Hydrochloride for Multiple Sclerosis Symptoms Return then Become Less Severe
After years of taking Rebif, my neurologist recommended this treatment to me. I was terrified of progressing to advanced RRMS andsecondary progressive MS, but after two years on the chemo with no side effects, my EDSS score went from 4.5 to 2.
3.7Patient Review
5/18/2009
Mitoxantrone Hydrochloride for Pain with Advanced Prostate Cancer Resistant to Hormones
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about mitoxantrone hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of chemo is mitoxantrone?

"Mitoxantrone is an anti-cancer drug that is classified as an "antitumor antibiotic.""

Answered by AI

How does mitoxantrone work in the body?

"Mitoxantrone is an injection that falls into the category of medications known as anthracenediones. This particular medication works to treat MS by hindering certain cells of the immune system from being able to reach the brain and spinal cord where they can cause damage. As for cancer, mitoxantrone work by stopping the growth and spread of cancer cells."

Answered by AI

What is mitoxantrone used for?

"Mitoxantrone injection is a medication used to treat advanced prostate cancer and acute nonlymphocytic leukemia. It is typically used in conjunction with other medications and belongs to a group of medications known as antineoplastics or cancer medications. Mitoxantrone is also sometimes used to treat multiple sclerosis."

Answered by AI

How long does mitoxantrone take to work?

"The average response time to mitoxantrone chemotherapy was 21 days, with 7 out of 15 dogs experiencing complete responses that lasted an average of 84 days."

Answered by AI

Clinical Trials for Mitoxantrone Hydrochloride

Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Image of OHSU Knight Cancer Institute in Portland, United States.

Fludarabine + Cytarabine + Idarubicin + Venetoclax for Acute Myeloid Leukemia

18 - 65
All Sexes
Portland, OR
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.
Phase 2
Waitlist Available
OHSU Knight Cancer InstituteCurtis A Lachowiez
Image of Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center in Cleveland, United States.

Rituximab + Tafasitamab + NK Cells for Non-Hodgkin's Lymphoma

18+
All Sexes
Cleveland, OH
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
Phase 1
Waitlist Available
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center (+1 Sites)Paolo Caimi, MDIncyte Corporation
Have you considered Mitoxantrone Hydrochloride clinical trials? We made a collection of clinical trials featuring Mitoxantrone Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of University of California, San Diego in La Jolla, United States.

SB-4826 for Non-Hodgkin's Lymphoma

18+
All Sexes
La Jolla, CA
The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This drug will be used alone in patients with solid tumors, and will be used alone or in combination with rituximab in patients with non-Hodgkin lymphomas. The main questions this clinical trial aims to answer are: What is the maximum dose of SB-4826 that can be used safely in patients with solid tumors and non-Hodgkin lymphomas, and will it work? How does SB-4826 work in people with cancer? How is SB-4826 absorbed, broken down, and excreted by the body? Participants will: Take drug SB-4826 every other day for up to 1 year; keep a diary of when they take SB-4826 at home; visit the clinic for checkups, tests, and fill out study questionnaires.
Phase 1 & 2
Waitlist Available
University of California, San DiegoPeter Vu, MD
Image of St. Jude Children's Research Hospital in Memphis, United States.

High Intensity Interval Training for Hodgkin's Lymphoma Survivors

10 - 25
All Sexes
Memphis, TN
This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated. Primary Objective: To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Feasibility will be assessed by: * Participation Rate: Number of eligible survivors approached who enroll. * Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.
Waitlist Available
Has No Placebo
St. Jude Children's Research HospitalAmy Berkman, MD
Have you considered Mitoxantrone Hydrochloride clinical trials? We made a collection of clinical trials featuring Mitoxantrone Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Tagraxofusp + Venetoclax + Azacitidine for Acute Myeloid Leukemia

18+
All Sexes
Boston, MA
The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence. The names of the study drugs involved in this study are: * Tagraxofusp (a type of CD123-directed cytotoxin) * Azacitidine (a type of standard of care cytidine nucleoside analog) * Venetoclax (a type of standard of care BCL-2 inhibitor)
Phase 1 & 2
Recruiting
Brigham and Women's Hospital (+1 Sites)Jacqueline Garcia, MDStemline Therapeutics, Inc.
Have you considered Mitoxantrone Hydrochloride clinical trials? We made a collection of clinical trials featuring Mitoxantrone Hydrochloride, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security